Consulta: subjectFacets:"Immunotherapy"
Registros recuperados: 9
Data/hora: 01/06/2024 17:21:03

Personal history of infections and immunotherapy: unexpected links and possible therapeutic opportunities
Provedor de dados: Institutional Archive of Ifreme (ArchiMer)
Autores: Jacqueline, Camille; Bonnefoy, Nathalie; Charriere, Guillaume; Thomas, Frederic; Roche, Benjamin.
The recent breakthroughs in the understanding of tumor immune biology have given rise to a new generation of immunotherapies, harnessing the immune system to eliminate tumors. As the typology and frequency of encountered infections are susceptible to shape the immune system, it could also impact the efficiency of immunotherapy. In this review, we report evidences for an indirect link between personal history of infection and different strategies of immunotherapy. In the current context of interest rise for personalized medicine, we discuss the potential medical applications of considering personal history of infection to design immunotherapeutic strategies.
Tipo: Text
Palavras-chave: Immunotherapy; Infections; Personalized medicine; Cancer vaccine; Immune checkpoints; Adoptive cell transfer.
Ano: 2018
URL: https://archimer.ifremer.fr/doc/00437/54865/57788.pdf

Post-exposure treatment of Ebola virus using passive immunotherapy: proposal for a new strategy
Provedor de dados: Journal of Venomous Animals and Toxins Including Tropical Diseases
Autores: Chippaux,Jean-Philippe; Boyer,Leslie V; Alagón,Alejandro.
Background Better treatments are urgently needed for the management of Ebola virus epidemics in Equatorial Africa. Methods We conducted a systematic review of the literature on the use of passive immunotherapy for the treatment or prevention of Ebola virus disease. We placed findings from this review into the context of passive immunotherapy currently used for venom-induced disease, and recent improvements in manufacturing of polyvalent antivenom products. Results Passive immunotherapy appears to be one of the most promising specific treatments for Ebola. However, its potential has been incompletely evaluated, considering the overall experience and recent improvement of immunotherapy. Development and use of heterologous serum derivatives could protect...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Ebola; Epidemics; Immunotherapy; Prophylaxis; Africa.
Ano: 2015
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1678-91992015000100203

Melanoma cutáneo: un campo de ensayo para la inmunoterapia y un desafío médico
Provedor de dados: Acta Bioquímica Clínica Latinoamericana
Autores: Mordoh,José.
El melanoma cutáneo es la neoplasia con mayor tasa de aumento. Los tratamientos quimioterápicos se han revelado en general ineficaces; sin embargo, la inmunoterapia juega un rol importante en el tratamiento del mismo. En esta revisión se abarcarán aspectos relacionados con el uso de diversas variantes de vacunas terapéuticas contra el melanoma, y se demostrará que son especialmente útiles en estadíos tempranos de la enfermedad.
Tipo: Info:eu-repo/semantics/other
Palavras-chave: Melanoma cutáneo; Inmunoterapia; Vacunas terapéuticas; Skin melanoma; Immunotherapy; Therapeutic vaccines.
Ano: 2009
URL: http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0325-29572009000300011

Cloning, expression, and analysis of the group 2 allergen from Dermatophagoides farinae from China
Provedor de dados: Anais da Academia Brasileira de Ciências
Autores: Yu-bao,Cui; Zhou,Ying; Weihong,Shi; Guifang,Ma; Yang,Li; Yungang,Wang.
To obtain the recombinant group 2 allergen product of Dermatophagoides farinae (Der f 2), the Der f 2 gene was synthesized by RT-PCR. The full-length cDNA comprised 441 nucleotides and was 99.3% identical to the reference sequence (GenBank AB195580). The cDNA was bound to vector pET28a to construct plasmid pET28a(+)-Der f 2, which was transformed into E. coli BL21 and induced by IPTG. SDS-PAGE showed a specific band of about 14kDa in the hole cell lysate. s estiated by chroatography, about 3.86 g of the recobinant product as obtained, which conjugated with serum IgE from asthmatic children. The protein had a signal peptide of 17 amino acids. Its secondary structure comprised an alpha helix (19.86%), an extended strand (30.82%), and a random coil (49.32%)....
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Dermatophagoides farinae; House-dust-mite allergy; Mite allergens; Der f 2; Allergen engineering; Immunotherapy; Bioinformatics.
Ano: 2010
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0001-37652010000400017

Successful use of a defined antigen/GM-CSF adjuvant vaccine to treat mucosal leishmaniasis refractory to antimony: a case report
Provedor de dados: Brazilian Journal of Infectious Diseases
Autores: Badaro,Roberto; Lobo,Iza; Nakatani,Maria; Muiños,Alvaro; M. Netto,Eduardo; Coler,Rhea N.; Reed,Steven G.
Immunotherapy has been proposed as a method to treat mucosal leishmaniasis for many years, but the approach has been hampered by poor definition and variability of antigens used, and results have been inconclusive. We report here a case of antimonial-refractory mucosal leishmaniasis in a 45 year old male who was treated with three single injections (one per month) with a cocktail of four Leishmania recombinant antigens selected after documented hypo-responsiveness of the patient to these antigens, plus 50mg of GM-CSF as vaccine adjuvant. Three months after treatment, all lesions had resolved completely and the patient remains without relapse after two years. Side effects of the treatment included only moderate erythema and induration at the injection site...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Leishmaniasis; Immunotherapy; Mucosal leishmaniasis.
Ano: 2001
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702001000400008

Co-culture of apoptotic breast cancer cells with immature dendritic cells: a novel approach for DC-based vaccination in breast cancer
Provedor de dados: Brazilian Journal of Medical and Biological Research
Autores: Zheng,Jin; Liu,Qiang; Yang,Jiandong; Ren,Qinyou; Cao,Wei; Yang,Jingyue; Yu,Zhaocai; Yu,Fang; Wu,Yanlan; Shi,Hengjun; Liu,Wenchao.
A dendritic cell (DC)-based vaccine strategy could reduce the risk of recurrence and improve the survival of breast cancer patients. However, while therapy-induced apoptosis of hepatocellular and colorectal carcinoma cells can enhance maturation and antigen presentation of DCs, whether this effect occurs in breast cancer is currently unknown. In the present study, we investigated the effect of doxorubicin (ADM)-induced apoptotic MCF-7 breast cancer cells on the activation of DCs. ADM-induced apoptotic MCF-7 cells could effectively induce immature DC (iDC) maturation. The mean fluorescence intensity (MFI) of DC maturity marker CD83 was 23.3 in the ADM-induced apoptotic MCF-7 cell group compared with 8.5 in the MCF-7 cell group. The MFI of DC co-stimulatory...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Breast cancer; Dendritic cells; Immunotherapy; Apoptosis; Doxorubicin.
Ano: 2012
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2012000600006

More than 10 years survival with sequential therapy in a patient with advanced renal cell carcinoma: a case report
Provedor de dados: Brazilian Journal of Medical and Biological Research
Autores: Yuan,J.L.; Wang,F.L.; Yi,X.M.; Qin,W.J.; Wu,G.J.; Huan,Y.; Yang,L.J.; Zhang,G.; Yu,L.; Zhang,Y.T.; Qin,R.L.; Tian,C.J.
Although radical nephrectomy alone is widely accepted as the standard of care in localized treatment for renal cell carcinoma (RCC), it is not sufficient for the treatment of metastatic RCC (mRCC), which invariably leads to an unfavorable outcome despite the use of multiple therapies. Currently, sequential targeted agents are recommended for the management of mRCC, but the optimal drug sequence is still debated. This case was a 57-year-old man with clear-cell mRCC who received multiple therapies following his first operation in 2003 and has survived for over 10 years with a satisfactory quality of life. The treatments given included several surgeries, immunotherapy, and sequentially administered sorafenib, sunitinib, and everolimus regimens. In the course...
Tipo: Info:eu-repo/semantics/report
Palavras-chave: Metastatic renal cell carcinoma; Sequential therapy; Targeted anticancer agents; Sorafenib; Sunitinib; Immunotherapy.
Ano: 2015
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2015000100034

p19Arf sensitizes B16 melanoma cells to interferon-β delivered via mesenchymal stem cells in vitro
Provedor de dados: Brazilian Journal of Medical and Biological Research
Autores: Da-Costa,R.C.; Vieira,I.L.; Hunger,A.; Tamura,R.E.; Strauss,B.E.
The immune stimulatory and anti-neoplastic functions of type I interferon have long been applied for the treatment of melanoma. However, the systemic application of high levels of this recombinant protein is often met with toxicity. An approach that provides localized, yet transient, production of type I interferon may overcome this limitation. We propose that the use of mesenchymal stem cells (MSCs) as delivery vehicles for the production of interferon-β (IFNβ) may be beneficial when applied together with our cancer gene therapy approach. In our previous studies, we have shown that adenovirus-mediated gene therapy with IFNβ was especially effective in combination with p19Arf gene transfer, resulting in immunogenic cell death. Here we showed that MSCs...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Gene therapy; Immunotherapy; Stem cell therapy; Adenovirus; P53; Interferon-β.
Ano: 2020
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2020000300601

Advances and challenges in therapeutic monoclonal antibodies drug development
Provedor de dados: Brazilian Journal of Pharmaceutical Sciences
Autores: Santos,Mariana Lopes dos; Quintilio,Wagner; Manieri,Tania Maria; Tsuruta,Lilian Rumi; Moro,Ana Maria.
The use of serum containing polyclonal antibodies from animals immunized with toxins marked the beginning of the application of antibody-based therapy in late nineteenth century. Advances in basic research led to the development of the hybridoma technology in 1975. Eleven years later, the first therapeutic monoclonal antibody (mAb) was approved, and since then, driven by technological advances, the development of mAbs has played a prominent role in the pharmaceutical industry. In this review, we present the developments to circumvent problems of safety and efficacy arising from the murine origin of the first mAbs and generate structures more similar to human antibodies. As of October 2017, there are 61 mAbs and 11 Fc-fusion proteins in clinical use. An...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Immunotherapy; CDR grafting; Phage display; Transgenic mice; Single B cell sorting.
Ano: 2018
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502018000700406